Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.09) by $0.63. The business earned $26.61 million during the quarter, compared to analyst estimates of $21.29 million. Momenta Pharmaceuticals had a negative return on equity of 8.20% and a negative net margin of 24.70%. Momenta Pharmaceuticals's quarterly revenue was up 34.1% compared to the same quarter last year. During the same period last year, the company earned ($0.35) earnings per share. View Momenta Pharmaceuticals' Earnings History.

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Momenta Pharmaceuticals.

8 equities research analysts have issued 12-month price targets for Momenta Pharmaceuticals' shares. Their forecasts range from $6.00 to $26.00. On average, they anticipate Momenta Pharmaceuticals' stock price to reach $17.00 in the next year. View Analyst Ratings for Momenta Pharmaceuticals.

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

• 1. Cowen and Company analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)
• 2. According to Zacks Investment Research, "Momenta’s Glatopa 20mg continues to perform well. We note that as per estimates from Sandoz, Glatopa 20 mg product has now captured approximately 40% share of the 20 mg glatiramer acetate market in the U.S, up from 30% at the end of 2015. In addition, a potential submission of M923 for approval in mid-2017 will boost investor confidence. Momenta’s share price has outperformed the Zacks classified Biomedical and Genetics industry in the last 12 months. Fourth quarter results were impressive as the company beat estimates on both top and bottom line.However, the issuance of a warning letter to manufacturer Pfizer for Glatopa was disappointing. The ANDA approval is now contingent on the satisfactory resolution of the compliance observations stated in the warning letter resulting in a delay in approval. The warning letter will remain a major over hang on the shares till the issue is solved." (3/8/2017)
• 3. Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
• 4. Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)

Some companies that are related to Momenta Pharmaceuticals include FibroGen (FGEN), Blueprint Medicines Corporation (BPMC), Foundation Medicine (FMI), Emergent Biosolutions (EBS), Medpace Holdings (MEDP), Global Blood Therapeutics (GBT), Genus plc (GNS), Genomic Health (GHDX), Esperion Therapeutics (ESPR), Immunomedics (IMMU), Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Cara Therapeutics (CARA), Editas Medicine (EDIT), TG Therapeutics (TGTX), CRISPR THERAPTC (CRSP) and Enanta Pharmaceuticals (ENTA).

Momenta Pharmaceuticals' management team includes the folowing people:

• Craig A. Wheeler, President, Chief Executive Officer, Director
• Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, Senior Vice President - Research, Chief Scientific Officer
• Scott M. Storer, Chief Financial Officer, Senior Vice President
• Bruce A. Leicher, Senior Vice President, General Counsel, Secretary
• Bruce L. Downey, Independent Director
• Corey N. Fishman, Independent Director
• Georges Gemayel Ph.D., Independent Director
• Steven C. Gilman Ph.D., Independent Director
• Jose-Carlos Gutierrez-Ramos Ph.D., Independent Director

Momenta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.59%), BlackRock Inc. (12.70%), Vanguard Group Inc. (8.62%), Primecap Management Co. CA (3.97%), State Street Corp (3.48%) and Palo Alto Investors LLC (2.49%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Momenta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sector Gamma AS, Schroder Investment Management Group, PNC Financial Services Group Inc., Wells Fargo & Company MN, AXA, SG Americas Securities LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Momenta Pharmaceuticals stock in the last year include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach and Richard P Shea. View Insider Buying and Selling for Momenta Pharmaceuticals.

Momenta Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Foresite Capital Management III LLC, Edmond DE Rothschild Holding S.A., Pier Capital LLC, JPMorgan Chase & Co., Tekla Capital Management LLC and Vanguard Group Inc.. View Insider Buying and Selling for Momenta Pharmaceuticals.

Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $17.65.